CF33-hNIS
AXP000099.1 · Oncolytic virus
- Platform
- chimeric orthopoxvirus (CF33)
- Originator
- City of Hope (Yuman Fong)
- Sponsor
- Imugene
Names
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- chimeric orthopoxvirus (CF33)
- Strain
- CF33
- Replication
- conditionally replicating
- Modifications
- thymidine kinase locus replaced by the hNIS expression cassette
- Transgenes
- SLC5A5 (hNIS)
- Route
- intratumoral, intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | Terminated | Phase 1 | 2022-05-17 | 2026-01-12 | 66 | Advanced Solid Tumor; Bile Duct Cancer; Cholangiocarcinoma; Metastatic Cancer; Solid Carcinoma; Solid Tumor; Solid Tumor, Adult |
| NCT05081492 | CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer | Active not recruiting | Phase 1 | 2021-10-18 | 2027-03-01 | 9 | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40933893 | hNIS-based imaging to monitor treatment with the novel oncolytic virus CF33-hNIS-antiPDL1 in humans with advanced triple negative breast cancer. | Frontiers in oncology | 2025 | cited by trial NCT05081492 |
| PMID 38028143 | CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study. | Therapeutic advances in medical oncology | 2023 | cited by trial NCT05081492 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41104781 | Oncolytic Properties of the Chimeric Poxvirus HOV-2 in Cholangiocarcinoma Models. | Journal of the American College of Surgeons | 2026 | name in title: HOV2 |
| PMID 41922086 | Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory. | Journal for immunotherapy of cancer | 2026 | name in title: CF33-hNIS |
| PMID 40782434 | CF33-hNIS-antiPDL1 enhances immunogenicity and anti-tumor efficacy in an orthotopic syngeneic pancreatic cancer mouse model. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2025 | name in title: CF33-hNIS |
| PMID 37019471 | Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases. | Journal for immunotherapy of cancer | 2023 | name in abstract: CF33-hNIS |
| PMID 37196156 | An Oncolytic Poxvirus Encoding hNIS, Shows Antitumor Efficacy and Allows Tumor Imaging in a Liver Cancer Model. | Molecular cancer therapeutics | 2023 | name in abstract: CF33-hNIS |
| PMID 37318642 | Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy. | Medical oncology (Northwood, London, England) | 2023 | name in title: VAXINIA |
| PMID 37762490 | Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients. | International journal of molecular sciences | 2023 | name in title: CF33-hNIS |
| PMID 34108669 | CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. | Cancer gene therapy | 2022 | name in title: CF33-hNIS |
| PMID 35024377 | A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer. | Molecular therapy. Methods & clinical development | 2022 | name in title: CF33-hNIS |
| PMID 35118191 | PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1. | Molecular therapy oncolytics | 2022 | name in title: CF33-hNIS |
| PMID 32032721 | Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer. | Journal of the American College of Surgeons | 2020 | name in title: CF33-hNIS |
| PMID 32158622 | Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. | Oncoimmunology | 2020 | name in title: CF33-hNIS |
| PMID 31061881 | A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression. | Molecular therapy oncolytics | 2019 | name in abstract: CF33-hNIS |
| PMID 8181900 | Noradrenergic modulation of lymphohematopoiesis. | International journal of immunopharmacology | 1994 | name in abstract: VAXINIA |
Notes
Trade-named VAXINIA. CF33 is a chimera assembled by co-infection with nine orthopoxviruses, so no single parent NCBI taxon is given. Phase 1 MAST study (NCT05346484) dosed patients intratumorally and intravenously; terminated January 2026.
How to cite
CF33-hNIS (AXP000099.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000099.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.